Is Relfydess FDA Approved? Status, Mechanism, and How It Compares to Dysport

Relfydess ships as a pre-filled, ready-to-inject liquid. Unlike Dysport and Botox (onabotulinumtoxinA), which require reconstitution with sterile saline, Relfydess eliminates the mixing step entirely. The formulation uses a proprietary stabilizer package designed to maintain potency without refrigeration, allowing room-temperature storage—a logistical advantage for practices managing inventory and reducing cold-chain dependency.

The active ingredient is abobotulinumtoxinA, the same neurotoxin complex as Dysport. However, Relfydess's liquid formulation may alter diffusion kinetics compared to Dysport's reconstituted powder. Early clinical data suggest a slightly faster onset (potentially 3–4 days versus 5–7 for Dysport) and comparable duration (12–16 weeks), though individual variation remains substantial.

Dosing and Unit Equivalence

Relfydess is dosed in units identical to Dysport—not 1:1 equivalent to Botox units. A typical forehead treatment with Relfydess ranges 20–25 units, similar to Dysport dosing. Practices already familiar with Dysport's diffusion profile and unit requirements will find the transition straightforward; the main operational change is eliminating reconstitution.

Regulatory and Clinical Context

The 510(k) approval pathway means Relfydess was not required to conduct new pivotal efficacy or safety trials; instead, Galderma demonstrated bioequivalence and manufacturing consistency relative to Dysport. This is a faster, lower-cost regulatory route than a PMA (Premarket Approval), which Botox and Dysport underwent years ago. The approval does not imply superiority—only that Relfydess meets the same safety and efficacy standards as its predicate device.

Competitive and Economic Implications

For medspa owners, Relfydess enters a three-player market: Allergan Aesthetics (Botox), Galderma (Dysport and now Relfydess), and Revance (DaxibotulinumtoxinA, approved 2023). Galderma's ready-to-use format is a convenience play, potentially reducing chair-side prep time and waste from partial vials. Pricing and rebate structures through Galderma's Aspire loyalty program will be critical to adoption; practices should verify current per-unit cost and volume incentives against existing Dysport contracts.

The liquid format also reduces the risk of reconstitution errors—a subtle but real compliance and quality-control advantage in high-volume practices.

Current Status and Verification

Relfydess is FDA-cleared for glabellar lines, crow's feet, and forehead lines in adults. Practices should confirm current pricing, availability, and any state-specific restrictions with Galderma directly, as market dynamics and insurance/rebate terms evolve. The product is not yet universally stocked by all distributors; verify supply chain readiness before committing to inventory.